Market Place
Sourcing Support
MHRA Approves Anzupgo® (Delgocitinib) Cream in Great Britain
03 Dec 2024 //
BUSINESSWIRE
LEO Pharma’s Anzupgo® Cream Approved in Switzerland
14 Nov 2024 //
BUSINESSWIRE
LEO Pharma Presents Adbry® and Delgocitinib Data at Conference
23 Oct 2024 //
BUSINESSWIRE
Germany Becomes First Country to Launch LEO Pharma’s Anzupgo Cream
15 Oct 2024 //
BUSINESSWIRE
LEO Presents Extensive Data of 5 Late Breaking Abstracts At EADV
25 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents Anzupgo® Data At EADV 2024
25 Sep 2024 //
BUSINESSWIRE
EC Approves LEO Pharma`s Anzupgo For Chronic Hand Eczema
23 Sep 2024 //
BUSINESSWIRE
Leo Pharma`s Anzupgo (delgocitinib) Receives Approval in Europe
19 Sep 2024 //
EMA
LEO Pharma Gets CHMP Nod For Anzupgo In Chronic Hand Eczema
25 Jul 2024 //
BUSINESSWIRE
Leo Pharma builds its case for JAK inhibitor cream delgocitinib
24 Jan 2024 //
FIERCE PHARMA
LEO Pharma Announces Positive Outcome of DELTA 3 Trial of Delgocitinib
30 Oct 2023 //
BUSINESSWIRE
Leo unveils detailed results on JAK cream win in hand eczema
13 Oct 2023 //
FIERCE PHARMA
EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in CHE
18 Aug 2023 //
BUSINESSWIRE
Leo Pharma scores in phase 3 trial for JAK inhibitor cream
13 Feb 2023 //
FIERCE PHARMA
LEO Announces Positive PIII Results From DELTA 2 Trial With Delgocitinib
10 Feb 2023 //
BUSINESSWIRE
LEO Pharma announces +ve results of Ph2b dose-finding study with delgocitinib
30 Oct 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.